AlphAIAlphAI — Financial news for AI agents
simplywall.stAUG 86 min read$CRSP

CRISPR Therapeutics (CRSP) Earnings Drew Fresh Interest, Is The Stock Below Fair Value?

Simply Wall St reports CRISPR Therapeutics (CRSP) drew renewed attention after it posted Q2 2026 results on Aug. 3. The company reported revenue of $10.18M and a reduced net loss of $91.15M. The stock rose 3.64% in one day and 11.52% over a week. A DCF model estimates fair value at $218.96 versus a $53.52 close.

Original reporting
simplywall.st
Published Aug 8, 2026, 6:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 8, 2026, 6:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CRSP
Neutral
medium confidence
Mentioned
$CRSP
Relevance
4/10
AlphAI data visualization · based on simplywall.st
Decision brief

The 30-second read

$CRSPNeutralLow
01

Why it matters

Traders may use the earnings numbers and the valuation framing to reassess downside risk versus upside optionality, but the article lacks new forward-looking catalysts (e.g., trial readouts, regulatory decisions, or updated guidance).

02

Market read

Earnings sparked renewed interest, but the main incremental content is valuation interpretation rather than a fresh fundamental catalyst.

03

What to watch

The article does not provide cash balance, guidance, burn rate, or trial/regulatory milestones that typically drive CRSP’s risk premium and near-term valuation.

Relevance 4/10Novelty 3/10Timing: post-earnings, after Q2 results reported Aug 3

Background

Simply Wall St discusses CRISPR Therapeutics’ Q2 2026 results and contrasts a DCF fair value estimate with market pricing using P/B.

Company-level read

Ticker impact

$CRSPNeutralMedium confidence
Context

CRISPR Therapeutics reported Q2 2026 results with revenue of $10.18M and reduced net loss, prompting renewed attention and valuation debate.

Expected impact

Likely modest, sentiment-driven volatility around earnings interpretation rather than a clear directional repricing.

Evidence & confidence

It provides earnings figures and a DCF vs market price comparison, but no new clinical, regulatory, or guidance datapoint beyond the reported quarter.

Market effects

Sector

Reinforces the biotech/gene-editing valuation debate between cash-flow discounting and book-value multiples.

Regional

No specific regional spillover beyond US-listed biotech sentiment.

Global

Limited; the piece is company-specific and does not cite global regulatory or trial developments.

Counterpoint

What could challenge this read

The DCF “deep discount” may be overly optimistic if future cash flows depend on timelines and success probabilities that remain highly uncertain for gene-editing programs.

Key entities

  • company
    CRISPR Therapeutics

    Subject of the article; reported Q2 2026 results and is evaluated via DCF and P/B valuation lenses.

  • product
    CASGEVY

    Mentioned as part of the pipeline/programs considered in the valuation discussion.

Read at source← All news

Related articles

SEP 8
$CRSPMedAI 8/10

Why CRISPR Therapeutics Stock Rocked the Market Last Month

CRISPR Therapeutics (CRSP) shares rose 19% in August following its Q2 earnings report. Sales of its blood disorder treatment Casgevy increased 78% to $76M, and the FDA expanded its approval. Revenue reached $10.2M, up from $892K a year ago, with a net loss of $91.5M. Analysts expected lower revenue and a larger loss. The company is developing treatments for hypertension and other disorders.

yahoo.com3 min
SEP 8
$CRSPMedAI 8/10

Where Will CRISPR Therapeutics Stock Be in 5 Years?

CRISPR Therapeutics (CRSP) reported $76M in Q2 2026 revenue from Casgevy, up 78% sequentially and 151% YoY. The company has a strong pipeline, including CTX310 for cardiovascular disease and Zugo-cel for autoimmune diseases. With $2.36B in cash and a $5.4B market cap, CRISPR has financial flexibility to advance multiple programs. Success in these areas could significantly increase its valuation by 2031, though risks remain.

yahoo.com3 min
AUG 30
$CRSPMedAI 8/10

CRISPR Therapeutics (CRSP) Stock May Look Rich Following Fresh CTX310 Data

CRISPR Therapeutics (CRSP) stock is down 52.7% over 5 years, despite recent gains. The company presented Phase 1a data for CTX310, which may boost confidence in its drug pipeline. However, the stock is considered overvalued on market multiples, trading at a P/B of 3.2x, above the biotech industry average. Investors are paying a premium for its pipeline potential, but clinical and regulatory risks remain significant.

simplywall.st3 min
AUG 28
$CRSPMedAI 8/10

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

CRISPR Therapeutics (CRSP) presented Phase 1a data for CTX310® at ESC Congress 2026, showing mean reductions of 79% in ANGPTL3, 48% in triglycerides, and 53% in LDL at the highest dose. The therapy was well tolerated with no serious adverse events. Data was also published in The New England Journal of Medicine. The company is advancing CTX310 in a Phase 1b trial and expects to provide an update in the second half of 2026.

globenewswire.com2 min
AUG 4
$CRSPMed

CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates

CRISPR Therapeutics (CRSP) reported a Q2 2026 loss of 94 cents per share, narrower than the Zacks estimate of a $1.10 loss. Revenue rose to $10.2 million, above the $7 million estimate. Vertex’s Casgevy sales were $76 million in Q2. CRSP ended June with $2.36 billion cash and said multiple pipeline updates are expected in H2 2026.

zacks.com6 min